Histiocytoses are a heterogeneous group of idiopathic diseases with a localized or disseminated accumulation of histiocytic cells and are classified into Langerhans cell histiocytosis (LCH) and non-Langerhans cell histiocytosis (N-LCH). Lesional cells in LCH are characterized by dendritic cell markers such as S-100 as well as Langerhans cell–specific features such as Birbeck granules and expression of CD1a, langerin, and fascin. Langerhans cell histiocytosis generally occurs during childhood, but an increasing incidence in adults has been reported.1 Multiorgan LCH is associated with a considerable mortality, and so new treatment options beyond established chemotherapy protocols are needed. Herein, we report 2 cases of LCH that did not respond to imatinib, a kinase inhibitor recently used to treat LCH2 and N-LCH.3
Wagner C, Mohme H, Krömer-Olbrisch T, Stadler R, Goerdt S, Kurzen H. Langerhans Cell Histiocytosis: Treatment Failure With Imatinib. Arch Dermatol. 2009;145(8):949–950. doi:10.1001/archdermatol.2009.164
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: